(MENAFN- GetNews) Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, Atypical Hemolytic Uremic Syndrome pipeline constitutes 5+ key companies continuously working towards ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the drug pipeline for the atypical hemolytic uremic syndrome. The report includes a detailed analysis of the ...

"Atypical Hemolytic Uremic Syndrome Pipeline"Following the success of terminal complement inhibitors like eculizumab and ravulizumab, the therapeutic focus in 2025 has shifted towards developing ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...

The FDA has approved Ultomiris (ravulizumab-cwvz; Alexion) for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) in adult and ...

ORLANDO, Fla.--(BUSINESS WIRE)--The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs, today announced ...

The Key Atypical Hemolytic Uremic Syndrome Companies in the market include - Alexion Pharmaceuticals, Hoffmann-La Roche, Novartis, NovelMed Therapeutics, and others. The Atypical Hemolytic Uremic ...

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. Study Overview: AstraZeneca is conducting a study titled The Burden of ...

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending ...

(RTTNews) - Alexion Pharmaceuticals Inc. (ALXN) said Friday that Japan has approved Ultomiris or ravulizumab for adults and children living with atypical hemolytic uremic syndrome or aHUS. atypical ...